首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VEGFA |
| Uniprot No | P15692 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-141aa |
| 氨基酸序列 | MAPMAEGGGQ NHHEVVKFMD VYQRSYCHPI ETLVDIFQEY PDEIEYIFKP SCVPLMRCGG CCNDEGLECV PTEESNITMQ IMRIKPHQGQ HIGEMSFLQH NKCECRPKKD RARQEKCDKP RR |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells"** by Ferrara, N. & Henzel, W.J. (1989)
摘要：首次纯化并克隆了VEGFA蛋白，揭示了其在促进血管内皮细胞增殖中的关键作用，为后续重组蛋白研究奠定基础。
2. **"Vascular endothelial growth factor: structure-function and biological activity"** by Holmes, K. et al. (1995)
摘要：系统分析重组VEGFA的结构域与功能关系，证实其通过结合受体KDR/Flk-1激活血管生成信号通路。
3. **"Recombinant VEGF121 treatment induces angiogenesis in non-human primate models of limb ischemia"** by Byrne, A.M. et al. (2005)
摘要：报道重组VEGFA121在灵长类肢体缺血模型中促进新生血管形成，支持其作为治疗性蛋白的潜力。
4. **"VEGF-VEGFR system as a target for suppressing inflammation and other diseases"** by Shibuya, M. (2014)
摘要：综述VEGFA重组蛋白在病理微环境调控中的双重角色，包括促血管生成与炎症调控机制的研究进展。
Vascular endothelial growth factor A (VEGFA) is a pivotal signaling protein involved in angiogenesis (formation of new blood vessels) and vascular permeability. It belongs to the VEGF family, which plays critical roles in embryonic development, tissue repair, and pathological conditions such as cancer and retinopathy. VEGFA binds to tyrosine kinase receptors (VEGFR1 and VEGFR2) on endothelial cells, triggering downstream pathways that promote cell proliferation, migration, and survival. Its dysregulation is linked to diseases like age-related macular degeneration, diabetic retinopathy, and tumor growth.
Recombinant VEGFA protein is produced using genetic engineering techniques, typically through expression in mammalian cell lines (e.g., HEK293 or CHO cells) or bacterial systems like *E. coli*. The recombinant form retains the biological activity of native VEGFA, enabling research and therapeutic applications. For instance, it is widely used in *in vitro* and *in vivo* studies to investigate angiogenesis mechanisms, screen anti-angiogenic drugs, or optimize tissue engineering strategies. Conversely, inhibitors targeting VEGFA (e.g., bevacizumab, ranibizumab) are FDA-approved therapeutics for cancer and ocular diseases.
The production of recombinant VEGFA often involves purification steps like affinity chromatography, ensuring high purity and minimal endotoxin levels. Variants such as VEGF165 (the predominant isoform) are commonly generated, with or without tags (e.g., His-tag) for detection or purification. Challenges include maintaining protein stability and post-translational modifications (e.g., glycosylation) critical for receptor binding. Despite these hurdles, recombinant VEGFA remains indispensable for advancing biomedical research and developing targeted therapies for vascular-related disorders.
×
